These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 15329912)

  • 1. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors.
    Kreth FW; Faist M; Grau S; Ostertag CB
    Cancer; 2006 Mar; 106(6):1372-81. PubMed ID: 16470609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
    Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
    Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
    Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
    Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.
    Luyken C; Blümcke I; Fimmers R; Urbach H; Wiestler OD; Schramm J
    Cancer; 2004 Jul; 101(1):146-55. PubMed ID: 15222000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
    Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
    Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma.
    Combs SE; Schulz-Ertner D; Thilmann C; Edler L; Debus J
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):797-802. PubMed ID: 15936562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
    Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
    Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B; Presler M; Matuszewski M
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.